Topic: Atherosclerosis - Primary Care
Wednesday, 04 January 2017
Adding evolocumab to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with coronary artery disease, according to results from the GLAGOV phase 3 trial.
Wednesday, 04 July 2018
Using a healthy lifestyle smartphone application helps to slow artery ageing, according to results from the EVIDENT II trial presented at the recent EuroHeartCare 2018 conference.
Friday, 30 June 2017
The leading UK cardiovascular conference for the whole primary care team. Expert presenters and a down-to-earth approach help health professionals translate the latest evidence into daily practice and optimise patient care. Participants also receive 9 hours CPD credits. Book now to attend this inspirational event and take advantage of our Early Bird discount.
Thursday, 16 August 2018
A large, multicentre randomised control trial comparing combination low-dose rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily) in people with stable peripheral arterial disease (PAD) or carotid artery disease (CAD) showed that combination therapy reduced the composite primary outcome of cardiovascular death, stroke or myocardial infarction and increased the risk of major bleeds compared with aspirin (100 mg once daily) alone.